Researchers in England say they have the first evidence that a drug can improve COVID-19 survival: A cheap, widely available steroid called dexamethasone reduced deaths by up to one third in severely ill hospitalized patients.
Researchers say they will publish results soon. The study is a large, strict test that randomly assigned 2,104 patients to get the drug and compared them with 4,321 patients getting only usual care.
The drug was given either orally or through an IV. After 28 days, it had reduced deaths by 35% in patients who needed treatment with breathing machines and by 20% in those only needing supplemental oxygen. It did not appear to help less ill patients.
“This is an extremely welcome result,” one study leader, Peter Horby of the University of Oxford, says in a statement. “The survival benefit is clear and large in those patients who are sick enough to require oxygen treatment, so dexamethasone should now become standard of care in these patients. Dexamethasone is inexpensive, on the shelf, and can be used immediately to save lives worldwide.”
Even though the drug only helps in severe cases, “countless lives will be saved globally,” says Nick Cammack of Wellcome, a British charity that supports science research.
“Dexamethasone must now be rolled out and accessed by thousands of critically ill patients around the world,” says Cammack, who had no role in the study. “It is highly affordable, easy to make, can be scaled up quickly and only needs a small dosage.”
— AP
Watch Docu Nation Season 2: Resilience
when you join the ToI Community
Support The Times of Israel's independent journalism and receive access to our documentary series, Docu Nation: Resilience, premiering December 12.
In this season of Docu Nation, you can stream eight outstanding Israeli documentaries with English subtitles and then join a live online discussion with the filmmakers. The selected films show how resilience, hope, and growth can emerge from crisis.
When you watch Docu Nation, you’re also supporting Israeli creators at a time when it’s increasingly difficult for them to share their work globally.
To learn more about Docu Nation: Resilience, click here.
Support ToI and get Docu Nation
Support ToI and get Docu Nation
Already a member? Sign in to stop seeing this
You're a dedicated reader
We’re really pleased that you’ve read X Times of Israel articles in the past month.
That’s why we started the Times of Israel eleven years ago - to provide discerning readers like you with must-read coverage of Israel and the Jewish world.
So now we have a request. Unlike other news outlets, we haven’t put up a paywall. But as the journalism we do is costly, we invite readers for whom The Times of Israel has become important to help support our work by joining The Times of Israel Community.
For as little as $6 a month you can help support our quality journalism while enjoying The Times of Israel AD-FREE, as well as accessing exclusive content available only to Times of Israel Community members.
Thank you,
David Horovitz, Founding Editor of The Times of Israel
Join Our Community
Join Our Community
Already a member? Sign in to stop seeing this